title: A dual strategy to improve psychotic patients' compliance using sustained release quetiapine oral disintegrating tablets.
abstract: Quetiapine (QT) is a short acting atypical antipsychotic drug effective in schizophrenia and bipolar disorder. This study aims at designing a novel dosage form of sustained release taste-masked QT orally disintegrating tablets (ODTs) based on solid lipid micro-pellets (SLMPs). QT SLMPs were prepared using the hot melt extrusion technique and utilizing three lipid carriers: Compritol, Precirol and white beeswax either alone or in mixtures. They showed sustained QT release and a taste masking effect. The selected QT SLMP was further blended with an aqueous solution containing polyvinylpyrollidone (2.5 %), croscarmellose sodium (2 %) and mannitol (50 %); it was then lyophilized into ODT in a mass ratio of 1:2, respectively. ODTs containing QT SLMPs showed: average wetting time (40.92 s), average oral disintegration time (21.49 s), average hardness (16.85 N) and also imparted suitable viscosity to suspend pellets during the lyophilization process. In conclusion, lyophilization is a promising technique for the formulation of multiparticulate systems into ODTs.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Refaat
authors.forename: Magda
authors.initials: M
authors.lastname: Sokar
authors.forename: Fatma
authors.initials: F
authors.lastname: Ismail
authors.forename: Nabila
authors.initials: N
authors.lastname: Boraei
mesh_terms: D000284:Administration, Oral; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D004075:Diglycerides / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000009:adverse effects; D065546:Drug Liberation; D004355:Drug Stability; D004356:Drug Storage; D005079:Excipients / Q000737:chemistry*; D005227:Fatty Acids / Q000737:chemistry; D005612:Freeze Drying; D006244:Hardness; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D055118:Medication Adherence; D000069348:Quetiapine Fumarate / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D013649:Taste; D014783:Viscosity; D014885:Waxes / Q000737:chemistry
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D004075:Diglycerides; D005079:Excipients; D005227:Fatty Acids; D008055:Lipids; D014885:Waxes; C086409:glyceryl behenate; D000069348:Quetiapine Fumarate; C038228:beeswax; C009032:precirol